Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony J Rodgers

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
HIV Clinical Trials|August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRKEdwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.
The Lancet. Infectious Diseases|September 22, 2011
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialJoseph J Eron, Jürgen K Rockstroh, Jacques Reynes, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
HIV Clinical Trials|August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRKEdwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analysesJeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.
The Lancet. Infectious Diseases|September 22, 2011
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialJoseph J Eron, Jürgen K Rockstroh, Jacques Reynes, et al.
Pageof 2